Phathom Pharmaceuticals (Nasdaq: PHAT) announced the start of patient screening for pHalcon-NERD-302, a Phase 3 clinical study evaluating an as-needed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE